SOLARA - SOLARA ACTIVE PHARMA SCIENCES LIMITED Share Price

In the Q4 FY26 earnings conference call, Solara Active Pharma Sciences Limited management highlighted a strong performance, reporting the highest revenue, gross margins, and EBITDA over the past eight quarters. CEO Sandeep Rao indicated a 12% sequential growth in revenues, reaching INR 392 crores, alongside a significant 65% growth in EBITDA, totaling INR 61 crores. The EBITDA margin stood at 16%, with gross margins at 47%, indicating improved profitability from their base business, which operates at a 26% EBITDA margin and 54% gross margins.

Management indicated ongoing challenges in the ibuprofen segment, where they faced persistent headwinds resulting in negative EBITDA. A strategic review for the ibuprofen business is underway, with bankers appointed to explore strategic options, expected to conclude within the next two quarters. Consequently, plans for the carve-out of the polymers segment in the CRAMS business are currently on hold.

Looking ahead, while management refrained from providing specific financial projections for FY27 and FY28, they expressed optimism in maintaining the momentum of positive growth from Q4 FY26. They noted a focus on operational efficiencies, strategic customer engagements, and prudent financial management to chase sustainable growth. The aim is to achieve a debt-free status by FY29, having already reduced debt by approximately INR 158 crores in FY26, a 21% decrease.

Key forward-looking points include the expectation of ongoing enhancements in operational leverage due to existing capacity (approximately 30% currently under-utilized) and a commitment to filing four to five new DMFs annually starting in FY27, with potential revenue impacts anticipated around FY29 to FY30. The management team remains focused on building a performance-oriented organization while cautiously navigating the challenges within the ibuprofen business.

Here are the major questions and detailed answers from the Q&A section of the Solara Active Pharma Sciences Limited earnings transcript:

1. Question: "How much of the improvement reflects a structural change versus temporary factors like inventory restocking or favorable product mix?"

   Answer: I can assure you that our revenue growth of 12% from the base business is fundamentally robust, supported by a healthy order book. The increased utilization across our facilities is indicative of sustainable performance and not driven by transient factors.

2. Question: "What type of strategic options for the ibuprofen business are we looking at?"

   Answer: We are exploring various pathways, including finding a buyer who can better manage the ibuprofen business or converting it into a multiproduct facility. We expect to reach a conclusion in H1 of this financial year regarding these strategic options.

3. Question: "Can you elaborate on the commissioning of the Vizag facility?"

   Answer: The Vizag plant has been mothballed since 2024. We are currently assessing whether to use it for ibuprofen or other products after we finalize our strategic options. Further clarity will be provided by H1 2027.

4. Question: "What is the expected steady state EBITDA margin for the base business in the next few years?"

   Answer: We anticipate maintaining a steady state EBITDA margin of around 25% going forward. This has been consistent over the past few quarters and should hold true in the near future.

5. Question: "What plans do you have regarding the R&D spending on the API business?"

   Answer: We have invested about INR 200 crores over the last four years, but we have not seen meaningful new filings. We plan to revive our R&D efforts with a focused pipeline, aiming for 4 to 5 DMF filings each year starting in FY27. The impact of these efforts will likely be seen between FY29 to FY30.

6. Question: "How do you see the growth of the base business going forward, and can we expect a growth rate of 15-20%?"

   Answer: While I won't provide specific guidance, we aim to sustain and potentially improve upon our recent performance. Our growth will hinge on expanding the existing business and enhancing operational efficiencies, but an exact percentage remains uncertain.

7. Question: "What are the ongoing expenses for the mothballed Vizag facility?"

   Answer: We incur annual fixed costs between INR 12 to 15 crores for the Vizag facility, even while it remains out of operation.

8. Question: "How does the company view the necessity of pursuing backward integration for ibuprofen?"

   Answer: Given that ibuprofen is a commodity business generating negative EBITDA, our focus is primarily on enhancing our base business with a much higher margin. Investing in ibuprofen, which involves backward integration, does not align with our strategic priorities at this moment.

These summaries encapsulate the key points from the earnings call conversation, providing insight into the company's current state and future direction.